The United Kingdom has authorised the Alzheimer’s drug Leqembi, saying it’s the first medicine to show some impact in slowing the progression of the neurodegenerative disease.
But the British government likely will not be paying for it after an independent agency separately issued draft guidance concluding the benefits of Leqembi “cannot be considered good value for the taxpayer”.
#British #drug #regulator #approves #Alzheimers #drug
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
